We identified a discrete number of microRNAs differentially expressed in benign or malignant mesothelial tissues. We focused on mir-145 whose levels were significantly downregulated in malignant mesothelial tissues and malignant pleural mesothelioma (MPM) cell lines as compared to benign tissues (pleura, peritoneum or cysts). We show that promoter hyper-methylation caused very low levels in MPM cell lines and specimens. Treatment of MPM cell lines with mir-145 agonists negatively modulated some protumorigenic properties of MPM cells, such as clonogenicity, cell migration and resistance to pemetrexed treatment. The main effector mechanism of the clonogenic death induced by mir-145 was that of accelerated senescence. We found that mir-145 targeted OCT4 via specific binding to its 3 0 -UTR. Increased intracellular levels of mir-145 decreased the levels of OCT4 and its target gene ZEB1, thereby counteracting the increase of OCT4 induced by pemetrexed treatment which is known to favor the development of chemoresistant cells. In line with this, reintroduction of OCT4 into mimic-145 treated cells counteracted the effects on clonogenicity and replicative senescence. This further supports the relevance of the mir-145-OCT4 interaction for the survival of MPM cells. The potential use of mir-145 expression levels to classify benign vs malignant mesothelial tissues and the differences between pemetrexed-induced senescence and that induced by the re-expression of mir-145 are discussed.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a tumor originating from the mesothelial surfaces of the lung and characterized by an overall bad prognosis. 1 Chronic inflammation (consequent to asbestos exposure) and genetic predisposition are major players in MPM pathogenesis. 2 Additionally, because of the use of asbestos in the '70s, the incidence of MPM is expected to peak in the next few years. 2 Two main features influence the prognosis of MPM: first, its silent clinical progression, which leads to very late diagnosis and thus strongly limits therapeutic intervention (i.e., surgical resection). Second, its extreme resistance to current chemotherapeutic agents, which dramatically hampers the disease-free-survival of the treated patients. 3, 4 Therefore, identification of diagnostic biomarkers for MPM would be relevant for early diagnosis and patient stratification, in addition to contributing to our understanding of the basic mechanisms of MPM progression.
MicroRNAs (miRs) are short (17-22 nucleotides) noncoding RNAs that regulate gene expression by inhibiting protein translation, through base-pairing mediated interaction with the 3 0 UTR of target mRNAs. 5, 6 Given their ability to simultaneously target multiple genes/pathways, transient or stable modulation of intracellular microRNA levels is a powerful way to transduce adaptive stimuli leading to broad changes in pathway activation.
Growing evidence suggest that microRNAs play a major role in oncogenesis, with either tumor suppressor or tumor-promoting modalities. [7] [8] [9] MicroRNAs are much more stable than mRNAs and this phenomenon allows an assessment of their expression levels retrospectively from frozen or fixed tissues. This feature, together with their rather tissue-specific expression, has prompted the study of microRNAs expression levels as an important diagnostic and prognostic tool for a number of solid and non-solid malignancies. 9 Additionally, the study of cancer-associated microRNAs may prove useful in order to elucidate the mechanism(s) behind cell transformation. For example, the identification of low levels of mir-29c* in MPM has provided both a prognostic tool for epithelial MPM and has pointed to aberrant chromatin methylation for the progression of MPM. regulated in a number of solid tumors, including prostate and bladder tumors, endometrial adenocarcinomas and gliomas. [11] [12] [13] [14] The homeodomain-containing transcription factor OCT4 is among the multiple targets of mir-145. 13, 15 The OCT4 gene (also named POU5F1) plays an important role in activating self-renewal gene programs in embryonic tissues and stem cells. 16 OCT4 is found overexpressed in poorly differentiated and high-grade tumors, with potential to support aberrant proliferation, tumor initiation and chemoresistance. [17] [18] [19] [20] [21] These properties have been shown to reside in its ability to control epithelial to mesenchymal transition (EMT) 22 as shown in mouse models of metastatic colon cancer. 23 In fact, RNAi-based downregulation of OCT4 in vitro affects growth and tumorigenicity of ovarian cancer cell lines. 24 We found here that mir-145 has the potential to modulate many in vitro pro-tumorigenic features of MPM cells, including growth, clonogenicity and resistance to pemetrexed treatment. Additionally, transfection of mimic-145 into MSTO-211H cells strongly reduced tumor engraftment in vivo. Induction of replicative senescence accounted for the clonogenic death induced by the treatment of MPM cells with mir-145 agonists. Mir-145 directly targeted OCT4 and, indirectly, its EMT-promoting target ZEB1 in MPM cells and the levels of mir-145 and OCT4 inversely correlated in vivo. OCT4 targeting is crucial to the anticancer properties of mir-145. In fact, mimic-145 expression counteracted the increase of OCT4 in pemetrexed resistant MPM cells. Additionally, overexpression of OCT4 at least partially rescued the effects of mimic-145 on the clonogenicity and replicative senescence of the targeted MPM cells. Promoter hyper-methylation may contribute to the low levels of mir-145 in MPM cells and malignant MPM tissues. In summary, in this work, we have identified mir-145 downregulation as a characteristic trait of malignant vs benign mesothelial tissues. Additionally, we provide insights into the possible contribution of mir-145-OCT4 interaction to the transformed phenotype of MPM cells.
RESULTS

Identification of microRNAs differentially expressed among malignant and benign mesothelial tissues
We performed an unbiased microRNA screening of MPM specimens (n ¼ 29) and mesothelial benign tissues (mesothelial cysts, n ¼ 12) (Figure 1 ). In Table 1 the main histoclinical features of cysts and MPMs are reported. As expected by the reported incidence distribution of mesothelioma subtypes in western populations 25 more than 80% of cases were represented by the epithelioid mesothelioma (Table 1 ). All the analyzed specimens were derived from surgically resected, naïve -treated patients. Our analysis revealed striking differences in the microRNA expression profile of benign vs malignant mesothelial tissues and allowed us to identify a discrete number of microRNAs (n ¼ 19) which showed statistically significant opposite modulation in benign vs malignant tissues ( Figure 1a , heat map). PCA analysis confirmed the ability of the 19 selected microRNAs to discriminate between the benign and malignant tissues. This was particularly evident on the first component, accounting for 42.24% of the total variance (Figure 1b) . Among the differentially expressed microRNAs, a larger fraction showed higher levels in benign lesions (n ¼ 13) while a restricted number showed strong downregulation in the malignant tissues (n ¼ 6) (Figure 1a) . We focused on microRNA-145 (mir-145), because it showed the highest intensity values in its subgroup and because its modulation in our samples suggested the potential to act as a tumor suppressor. Additionally, mir-145 has been recently shown to modulate EMT, a key feature of MPM. 26, 27 Mir-145 is downregulated in MPM specimens and MPM cell lines but not in untransformed mesothelial cells We validated the previous results in two ways (Figure 1) . We validated the previous results in two ways. Firstly, we assessed the levels of mir-145 by quantitative PCR on unmatched MPM and pleural biopsies obtained from patients (n ¼ 20, of which 6 MPM and 14 benign tissue) not belonging to the first set analyzed ( Figure 1c) . As shown by the box plot (Figure 1c) , we found that mir-145 expression was significantly downregulated in this validation group, thus confirming our initial findings. Secondly, we assessed the mir-145 levels in snap-frozen matched pair samples (n ¼ 36) of peritoneal mesothelium vs MPM (Figure 1d ). This, again, revealed that mir-145 levels were significantly lower in the matched tissues (Po0.001) (Figure 1d ). In summary, our analysis revealed a statistically significant downregulation of mir-145 levels in MPM as opposed to the benign tissues, irrespectively of whether the latter was derived from cysts, normal mesothelium or peritoneal mesothelium from the same patient ( Figure 1 ). Mir-145 downregulation was observed in both paraffin-embedded MPM material and from snap-frozen sections. Additionally, the analyzed specimens were derived from three independent institutions (see discussion), thus strengthening further our results. To facilitate a functional characterization of mir-145 in MPM, we tested whether mir-145 downregulation was conserved in representative MPM cell lines as well (Figure 1e ). Quantitative PCR (Q-PCR) analysis showed that mir-145 expression was deeply downregulated in three MPM cell lines (MSTO-211H, NCI-H2052 and NCI-H28) when compared to untransformed mesothelial cells (HMC) (Figure 1e ). Of note, the MPM cell lines were different both in histologic type (epithelioid, sarcomatoid and byphasic) and growth properties (ATCC.org). This suggests that mir-145 downregulation is independent of MPM type and that our in vitro system could recapitulate what observed is in the initial microRNA screening of the patient samples ( Figure 1 and Table 1 ). Therefore, we decided to use the mentioned MPM cell lines to characterize the effect of mir-145 downregulation on MPM cells.
Re-expression of mir-145 affects viability and clonogenicity and migration of the MPM cell lines The broad downregulation of mir-145 in the malignant mesothelial tissues (as compared to the benign ones) suggested that mir-145 might act as a tumor suppressor (Figure 2 ). Therefore, we hypothesized that increased levels of mir-145 could counteract some of the malignant features of the MPM cell lines. To this aim, we transfected control-or mir-145 molecules in MSTO-211H, NCI-H2052 and NCI-H28 MPM cell lines (Figure 2 and Supplementary Figure 1A) . No significant increase of apoptotic cells was observed in either MSTO-211H and NCI-H2052 treated with mimic-145, as compared to their ctrltransfected counterparts (Supplementary Figure 1B) . To detail the observed effect on cell growth, we performed clonogenic assays from the same MPM cell lines (Figure 2a, middle and right panels) . The clonogenic assay is useful to assess the long-term in vitro tumorigenic capacity of transformed cells in a way independent of acute toxic effects due to liposome transfection. This revealed a strong inhibition of colony forming ability in the cell lines Finally, we evaluated the effect of mir-145 transfection on the migratory properties of MPM cells. Transwell cell migration assays revealed that the migration of NCI-H2052 and MSTO-211H transfected with mir-145 was strongly reduced, as compared to control-transfected counterparts (Figure 2b , left and right panels, Po0.05). Inhibition of cell migration was also observed by scratch assays as well at early time points (Supplementary Figure 2 , left and right panels). We could not test the NCI-H28 cell line in those assays, since the latter cells did not show significant migratory properties at steady state (unpublished observations). Altogether, these observations revealed that forced expression of mir-145 in transformed mesothelial cells affected three protumorigenic features, namely cell growth, clonogenicity and cell migration. Further, to evaluate if the observed effects of mir-145 by western blotting the levels of lamin B1, acetylated Histone H3 (AcH3K9) and p21 protein in ctrl-and mimic-145 treated MSTO-211H and NCI-H2052 cells. This revealed a significant reduction of both lamin B1 and AcH3K9 and induction of the p21 proteins in both mesothelioma cell lines transfected with mimic-145 (as compared to ctrl-transfected cells) ( Figure 3b ). Lastly, we observed increased formation of senescence-associated heterochromatin foci in the mimic-145 transfected cells (Figure 3c ). Senescenceassociated heterochromatin foci are specialized domains of facultative heterochromatin, known to contribute to senescenceassociated cell growth arrest by sequestering and silencing proliferation-promoting genes. All the observed changes are strongly suggestive of replicative senescence. [28] [29] [30] [31] [32] [33] Altogether, these observations support the idea that mir-145 expression induces senescence in MPM cells and that induction of replicative senescence may mediate the anticlonogenic effects of mimic-145 transfection.
Mir-145 targets OCT4 in MPM cells
The observed biological effects of mir-145 expression on MPM cell lines prompted us to investigate which gene products could mediate its effects ( Figure 4 ). Literature mining and in silico analysis with multiple target finding algorithms revealed several targets of mir-145 with relevance for cancer development (unpublished observations). We focused on OCT4 because of its involvement in modulating aggressive features of solid tumors. 19, 20, 23 We and others have previously shown that increased OCT4 levels correlate with the resistance of mesothelioma cells to pemetrexed in vitro. 34, 35 In addition, the acquisition of an hypermigratory phenotype is a main feature of transformed cells and requires the reactivation of pathways governing the EMT. 36 Initially, we confirmed targeting of the OCT4 3 0 UTR region by mir-145 by assessing the luciferase activity of HEK293 cells co-transfected with a double luciferase reporter (whose activity was driven by the OCT4 3 0 UTR) and a mir-145 expression vector (Figure 4a ). This revealed that transfection of the mir-145 significantly affected the translation of the luciferase mRNA in the targeted cells, as shown by a drop of the enzyme activity (Figure 4a) . Additionally, such effect was specific for mir-145, since it was abolished in cells transfected with a mutant 3 0 UTR construct unable to bind to mir-145 ( Figure 4a ). Next, we analyzed by western blotting the protein levels of OCT4 in controlvs mimic-145 transfected MST0-211H and NCI-H2052 cells. Our analysis revealed that mir-145 overexpression affected the protein levels of OCT4 (Figure 4b ). We also tested the effect of mimic-145 on exogenously expressed OCT4 in both MPM cell lines, by transfecting an OCT4 expression vector harboring a wt 3 0 UTR . 37 in the mimic-145 treated cells. This confirmed a specific decrease of the exogenously expressed OCT4 protein in the mimic-145 transfected cells (Figure 4b ). Further, we confirmed the downregulation of OCT4 by staining MSTO-211H (and NCI-H2052) cells co-transfected with GFP and mimic-145 with anti-OCT4 antibodies (Figure 4c ). This in fact showed a significant drop of OCT4 staining in the (GFP-positive) mimic-145 transfected cells (Figure 4c , Po0.05). Downregulation of OCT4 per se is compatible with the biological effects of mimic-145 we observed in vitro, with regard to the inhibition of cell growth, migration and clonogenicity ( Figure 2 ). In fact, OCT4 has been recently shown to control the expression of pivotal EMT promoting genes, including ZEB1, whose expression is relevant for MPM progression. 26 Western blotting analysis of lysates derived from control-and mimic-145 transfected cells revealed in fact significantly lower levels of ZEB1 protein in both mimic-145 treated MSTO-211H and NCI-H2052 cells (Supplementary Figure 3) . Lastly, we performed FACS staining of ctrl-and mimic-145 transfected MSTO-211H and NCI-H2052 cells (Figure 4d and data not shown). This revealed that mimic-145 transfection strongly reduced the number of OCT4-positive cells (8.94 ± 2.2% vs 1.94 ± 0.8% for ctrl-and mimic-145 transfected cells, respectively) (Figure 4d, upper panel) , therefore mirroring the previous results. We noticed a significant increase of the side scatter values of the mimic-145 transfected cells. It was considered when gating the cell populations and staining them with the control (isotype matched) antibody (Supplementary Figures 4A  and B) . This increase may reflect a change in the granularity of the mimic-145-treated cells due to their presenescent state. In summary, mimic-145 treatment of MPM cell lines affected the levels of endogenous OCT4 as well as the levels of the exogenously expressed protein.
Mir-145 and OCT4 expression levels inversely correlate in vivo Since the forced expression of mir-145 triggers OCT4 downregulation, we predict that lower mir-145 levels may correlate with increased expression of OCT4 in vivo (Figure 4e) . To verify this, we performed immunohistochemistry staining for OCT4 of paraffin embedded sections derived from some of the same samples used for our initial microRNA screening (Figure 1a) , for which the levels for mir-145 were previously determined (Figure 1a) . This showed that, as compared to the reference benign tissues (cysts), the levels of OCT4 were higher in all the MPM samples ranging from OCT4 antagonizes the miR-145-mediated suppression of MPM protumorigenic features To correlate the anticancer effects of mimic-145 with its activity toward the OCT4 gene product, we hypothesized that mimic-145 may antagonize the increase of OCT4 induced by pemetrexed treatment ( Figure 5 ). In fact, we and others have shown that emergence of chemoresistant clones within pemetrexed and cisplatin-treated MPM cell lines is linked to the upregulation of EMT and stemness-related genes, including OCT4. 34, 35 Therefore, we evaluated the ability of mimic-145 to affect the levels of OCT4 in pemetrexed treated cells. FACS staining of ctrl-and mimic-145 transfected MSTO-211H cells treated with pemetrexed revealed in fact a significant increase of the number of OCT4-positive cells in the ctrl-transfected ones (Figure 5a , left panel) (as compared to vehicle treated cells- Figure 4d ). This effect was strongly reduced in their mimic-145 transfected counterparts (Figure 5a , right panel) (24.94 ± 2.3 vs 6.22 ± 1.1%, respectively). Similar results were obtained when using NCI-H2052 cells (data not shown). Notably, in the pemetrexed treated cells, the previously observed effect of mimic-145 treatment on the side scatter of the cells was largely attenuated (Supplementary Figures 4C and D) . Next, we performed western blotting analysis with anti-OCT4 antibodies of lysates derived from the same cells as in Figure 5a : this revealed a significant decrease of OCT4 induction in MSTO-211H cells transfected with mimic-145 and treated with pemetrexed as compared to the similarly treated, ctrl-transfected cells (Figure 5b ). Based on these results, we predicted that overexpression of OCT4 could counteract the tumor-suppressive properties of the mimic-145. To this aim, we transfected control or mimic-145 treated MSTO-211H and NCI-H2052 cells with an OCT4 expressing vector (or with an empty vector) and we evaluated the properties of the transfected cells (Figures 5c and d) . We found that exogenous expression of OCT4 (and not that of the empty vector-EV) significantly attenuated the effect of mimic-145 on the clonogenicity of the transfected cells (please compare bars 2 and 4 of the histogram in Figure 5c , left panel). In fact, mimic-145 þ OCT4 transfected cells formed significantly more colonies than their control counterparts (17 ± 3% vs 38 ± 9% for EV þ mimic-145 vs OCT4 þ mimic-145, respectively, Po0.05) (Figure 5c ). Further, we evaluated the effect of OCT4 overexpression on the extent of cell senescence induced by the expression of mimic-145 (Figure 5d ). This revealed a significant reduction of the number of SA-bgalactosidase-positive cells in the OCT4 þ mir-145 expressing cells as opposed to the EV þ mir-145 transfected cells (Figure 5d , Po0.05). In summary, these observations further strengthen the physical and functional relevance of the mir-145-OCT4 interaction. Our observations are also reminiscent of previous work showing the potential for OCT4 overexpression to bypass the senescence of human primary breast cells. 38 Promoter methylation may contribute to mir-145 silencing in MPM cell lines We have found the levels of mir-145 downregulated in neoplastic mesothelial tissues and MPM cell lines, as opposed to benign tissues and untransformed mesothelial cells, respectively Figure 6 ). We next investigated how the levels of mir-145 could be downregulated in tumor samples. Therefore, we investigated the methylation status of all the DNA CpG islands represented within the regulatory regions of the mir-145 promoter (Figure 6a ). We performed pyrosequencing assays on normal and malignant mesothelial tissues, respectively (Figure 6b , upper and lower panels). This showed a general decrease of DNA methylation in all CpG islands analyzed (within the mir-145 promoter), in the mesothelia as compared to the mesothelioma tissues (average methylation: 46% ± 7% vs 83% ± 3%, for mesothelium vs mesothelioma, respectively, Po0.01) (Figure 6c) . The difference in methylation was even more evident for the CpG islands located closer to the transcription start site (Figure 6b , upper and lower panels). Further, we analyzed the methylation of the same CpG Figures 5A and B) which readily matched the increase of mir-145 levels as assessed by semi-quantitative PCR (Supplementary Figure 5C) . These observations support the idea that increased DNA methylation may be responsible for the low levels of mir-145 in both mesotheliomas and mesothelioma cell lines.
DISCUSSION
We investigated whether specific microRNAs could distinguish a large group of mesotheliomas from benign mesothelial lesions cysts, pleura or peritoneum. To reduce a possible 'singleinstitution bias' in the sample collection, the specimens used for both the screening and the validation have been independently derived from different institutions, all reference centers for mesothelioma therapy, and analyzed with two different platforms. The use of mesothelial cysts as normal control tissues is unprecedented. Mesothelial cysts are relatively rare structures composed of normal pleural or peritoneal mesothelium which develop as liquid-filled translucent fibrous walls lined by a single layer of mesothelial cells. 39 Therefore, mesothelial cysts may represent a valuable alternative to the use of immortalized cell lines or non-mesothelial tissues as a control. In the experimental system here used, we found that, with regard to mir-145 expression, all the sources of benign mesothelial tissue (cysts, pleural mesothelium, peritoneum) behaved similarly. Our initial screening has identified a number of microRNAs (n ¼ 19) whose levels of expression may segregate benign from malignant mesothelial tissues. Notably, some of the microRNAs identified in this study have been found by others and are already shown to possess the power to discriminate between lung adenocarcinoma and mesothelioma tissues (mir-141, mir-200c and mir-193). 40 This represents an indirect biological validation of our findings. On the other hand, some other microRNAs (mir-145, mir-204, mir-486-5p and mir-1287) have not been described yet for mesothelioma, to the best of our knowledge. We have focused on mir-145 for its potential to act pleiotropically as a tumor suppressor via targeting multiple relevant cancer genes. 12, [41] [42] [43] [44] [45] [46] [47] [48] We provide evidence here that hypermethylation of mir-145 regulatory region is responsible for the low levels of this microRNA in both malignant mesothelial tissues and mesothelioma cell lines. We found that overexpression of mir-145 by mimic compounds affected the levels of OCT4 and, indirectly, of its EMT-associated gene target, such as ZEB1. Both OCT4 and ZEB1 are intimately connected to the maintenance of stemness, EMT and cancer chemoresistance. [18] [19] [20] 24 Mir-145 downregulation conveys clear protumorigenic advantages to mesothelioma cells. Indeed, proliferation, clonal growth and migration of MPM cells are readily reduced by the transfection of 'mimic' compounds and in vivo tumorigenicity is reduced as well. All this is unprecedented for MPM and shows how microRNA modulation is complex and how a change in the levels of a single microRNA may affect multiple pathways, impinging on key tumor features. EMT and chemoresistance are in fact major determinants of mesothelioma development and progression. 26, 35 Mir-145 has multiple targets that are relevant to cancer progression. Although it is likely that multiple mechanisms underlie the anticancer effects of mir-145 re-expression in MPM cell lines, our observations suggest that OCT4 downregulation can be a main one. In fact, add-back of OCT4 into mimic-145 treated MPM cells at least partially restores the clonogenicity of the cells, while reducing significantly the number of senescent cells. These observations agree with the data from Beltran et al., showing that lentiviral expression of OCT4 in human mammary epithelial cells can 'bypass' the spontaneous senescence occurring in those primary cultures after few passages. 38 Conversely, the pro-senescence effects of mir-145 re-expression in MPM cells are reminiscent of the data from Bonifacio et al., 49 showing mir-145 upregulation in senescent human fibroblasts. Induction of chemoresistant cell populations is a side effect of pemetrexed and cisplatin treatment which limits their efficacy in vivo. This is fuelled by cytokines and growth factors secreted by senescent MPM cells in response to chemotherapy treatment, according to a senescence associated secretory phenotypenitha model. 35, [50] [51] [52] The resulting chemoresistant cells are endowed with very high levels of EMT and stemness genes, including OCT4 and ZEB1. 35 Indeed, we show here that pemetrexed treatment induces OCT4 and increases the number of OCT4-positive cells and the emergence of the latter cells may represent a mechanism of tumor progression. 35 Mimic-145 treatment may, at least partially, counteract this phenomenon, given its ability to downregulate OCT4 expression in pemetrexed treated samples.
One unanswered question of this study is whether mir-145 may act as a part of a larger group of microRNAs. In fact, we found that the distribution of the expression of mir-145 in our collected samples was strikingly similar to that of other 5 microRNAs (Figure 1a ). Therefore, it is possible that all or some of the mentioned microRNAs may act as a functional cluster by targeting converging pathways. This is supported by the fact that at least some of the microRNAs identified in this study are known to target common EMT-promoting factors (for example, mir-141 and 200c target ZEB1/2). [53] [54] [55] In this regard, it would be interesting in future work to investigate the relationship between mir-145 and the other microRNAs sharing a similar distribution, to unravel possible functional interactions. With regard to this, it is interesting that targeting of the ZEB1-EMT axis is a frequent-predicted function of the mentioned microRNAs. 56 This reflects the prominent role of these EMT players in MPM development. 26, 27 MATERIALS AND METHODS Sample collection 41 unmatched specimens (29 MPM and 12 mesothelial cysts) were collected from two different institutions in Italy (Regina Elena Cancer Institute, Rome and General Hospital S. Vincenzo, Taormina). All the specimens were from formalin fixed and paraffin embedded tissues and initial diagnosis confirmed by expert histopatologists. 20 fresh biopsies (14 normal pleura vs 6 MPM) were obtained from Regina Elena Cancer Institute. An additional 36 snap-frozen samples (matched peritonea vs MPM) were used as a validation set of the results obtained with the initial screening and derived from the New York University Medical Center, New York, United States. The patients were not treated with any previous radio or radio-chemotherapy, prior to undergoing surgery. Independent ethical committees from all the institutions approved the use of the samples.
RNA extraction, labeling and microarray hybridization RNA from formalin fixed and paraffin embedded tissue samples and cell lines was extracted using the miRneasy formalin fixed and paraffin embedded tissue kit (Qiagen, Hilden, Germany) and TRIZOL, respectively, following the manufacturer's instructions. TRIZOL was used for the extraction of snap-frozen tissue specimens as well. Total RNA (200 ng) coming from tissues was labeled and hybridized to Human miRNA Microarray V2 Rel.16 (Agilent, Santa Clara, CA, USA). Scanning and image analysis were performed using the Agilent DNA Microarray Scanner (P/N G2565BA) equipped with extended dynamic range (XDR) software, according to the Agilent miRNA Microarray System with miRNA Complete Labeling and Hyb Kit Protocol manual. Feature Extraction Software (Version 10.5) was used for data extraction from raw microarray image files using the miRNA_105_Dec08 FE protocol. For the matched peritonea vs MPM samples, samples were extracted with TRIZOL and five microgram of total RNA was processed as described elsewhere. 57 microRNA expression profiling and data analysis Analysis of the expression of 887 human microRNAs were performed using inhouse built routine by Matlab (The Mathworks Inc.). Signals were preprocessed with quantile normalization and log2 transformed. Samples with duplicates available were tested for quality control. Unpaired T-test and Wilcoxon test were used to identify differentially expressed features between mesothelioma samples and cysts. Deregulated miRNAs with P value less than 0.001 and false discovery rate less than 0.05 were selected. Unsupervised hierarchical clustering and Principal Component Analysis were used to separate different subgroups of samples basing on the identified signature. Validation of the signature was obtained by RT-PCR.
Target prediction
Diana mirPath (http://diana.cslab.ece.ntua.gr/pathways) using TARGETS-CAN 5 and PICTAR was used for the in silico putative target prediction of the selected microRNAs.
Cell lines and culture conditions
Human cell lines HEK293, MSTO-211H, NCI-H2052 and NCI-H28 were obtained from ATCC (Manassas, VA, USA). HMC human primary mesothelial cells were obtained from TEBU BIO (Tebu-Bio, Le Perray-en-Yvelines, France). All cell lines were cultured as monolayers at 371C and 5% CO 2 in DMEM/F12 þ GLUTAMAX (Invitrogen-GIBCO, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen-GIBCO), 5 mg/ml Insulin (Sigma, St Louis, MO, USA).
Cell transfection
Pre-miRNA precursor-negative control (Ambion-Life technology, Foster City, CA, USA) (Ctrl), Pre-miRNA145 (Ambion)(mimic145) at final concentration of 5 nM were transfected into the indicated MPM cell lines using Lipofectamine RNAiMAX (Invitrogen-GIBCO) according to the manufacturer's instructions. OCT4 expression vectors were from Warren et al., 
Cell viability assay
Manual counting and Trypan Blue dye exclusion assay that were used to assess cell growth and viability were indicated.
5-Aza-2
0 -deoxycytidine treatment Cells were plated in six-well plates on Day 0, and treated with a final concentration of 10 mM 5aza-2 0 -deoxycytidine (Sigma) on alternative days beginning from Day 1, until Day 3. The treated cells were harvested on Day 4.
DNA isolation, sodium bisulfite conversion and pyrosequencing Analysis Genomic DNA was isolated using the QIAamp DNA microKit (Qiagen). Sodium bisulfite modification of 450 ng DNA was performed using the DNA Methylation kit (Diatech Pharmocogenetics, Jesi (Ancona), Italy) according to the manufacturer's protocol. Modified DNA was subjected to PCR amplification of the specific promoter region of pri-miR-145 using the Corbett Life Science Rotor-Gene6000. The primer sequences are listed in Supplementary Table 1 . The resulting PCR products were analyzed by gel electrophoresis to confirm the size of the product and rule out the formation of primer dimers. The specific PCR products were then subjected to quantitative pyrosequencing analysis using a PyroMark Q96 ID (Qiagen) according to the manufacturer's protocol. The genomic location of the bisulfite pyrosequencing assays and the number of CpG sites investigated in each assay are shown in Figure 6 . The pyrosequencing analysis was performed with PyroMarker CpG software 1.0.11 (Qiagen).
In vitro migration assay
Wound-healing assay. Cells seeded in six-well tissue culture and grown to 95% confluence were wounded with a sterile 10-ml pipet tip to remove cells by one perpendicular line. PBS1 Â washing was used to remove loosely attached cells. Digital micrographs were taken after scratching at the indicated times.
Transwell migration assay. Migration assay was performed using a 24-well Boyden chamber with a non-coated 8-mm pore size filter in the insert chamber (BD Falcon, Franklin Lakes, NJ, USA). Cells (mimic 145-and control-transfected MSTO-211H) (5 Â 10 4 ) were suspended in 0.5 ml DMEM/F12 media without containing FCS and seeded into the insert chamber. Cells were allowed to migrate for 48 h into the bottom chamber containing 0.7 ml of DMEM/F12 media containing 5% FCS in a humidified incubator at 37 1C in 5% CO 2 . Migrated cells which had attached to the outside of the filter were visualized by staining with DAPI and counted.
Clonogenic assays MPM cell lines were grown to 70% confluence and pulse treated with the indicated drugs or transfected as indicated. Sixteen hours later, cells were detached and seeded at 500-1500 cells per well into six-well dishes (Corning-Costar, Tewksbury, MA, USA) in drug-free media. Fresh media (25%) was added every three days. Colonies were stained with crystal violet and colonies (450 cells) counted after 10-14 days.
cDNA synthesis and Q-PCR Total RNA was extracted using the TRIZOL reagents (Invitrogen-GIBCO). Real time-PCR of miRNA expression was performed using TaqMan MiRNA Assays (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. RNU6B and RNU49 were used as endogenous controls to standardize miRNA expression. For measurement of the precursor miRNA expression, PCR was performed using 2X red Mix DNA Polymerase MasterMix (RBC Bioscence, New Taipei, Taiwan) using the primers published by Zhang et al. 49 PCR was performed at 95 1C for 5 min, 32 cycles at 95 1C for 30 s, 60 1C for 40 s and 72 1C for 40 s followed by a final extension at 72 1C for 10 min. The PCR products were loaded on 2% agarose gel for analysis.
Lysate preparation and immunoblotting analyses Cells were lysed in buffer with 50 mM Tris-HCl pH 8, with 1% NP-40 (Igepal AC-630) 150 mM NaCl, 5 mM EDTA. Extracts were centrifuged at 14 000 Â rpm for 15 min to remove cell debris. Protein concentrations were determined by colorimetric assay (Bio-Rad, Hercules, CA, USA). Western blotting was performed using the following primary antibodies: anti-GAPDH (A228), TUBULIN (T6074) (Sigma); OCT4 C-10 (sc-5279) (Santa Cruz Technology, Dallas, TX, USA); OCT4A (C30A3), ZEB1 (D80D3), p21 (12D1), laminB1 (#16048) (Cell Signaling, Danvers, MA, USA); histone H3 Acetyl K9 (#61231), Histone H3 (#10799) (Abcam, Cambridge, UK). Secondary antibodies used were goat anti-mouse, conjugated to horseradish peroxidase (Amersham Biosciences, Piscataway, NJ, USA). Immunostained bands were detected by chemiluminescent method (Pierce, Rockford, IL, USA).
SA-b-gal staining SA-b-galactosidase staining was performed on adherent cells according to the manufacturer's instructions (Cell Signaling).
Immunofluorescence microscopy Cells (5 Â 10 3 cells per chamber) were seeded into eight-chamber culture slides (BD Falcon). The next day, cells were rinsed with ice-cold PBS and fixed with 4% paraformaldehyde for 10 min at room temperature followed by permeabilization with 0.1% Triton X-100. The cells were subjected to immunofluorescence staining with Oct-3/4 prediluted monoclonal antibody (PM 313 AA, Biocare Medical, Concord, CA, USA) for 2 h at room temperature. The cells were then washed with cold PBS three times for 3 min each, and counterstained with DAPI (4 0 ,6-diamidino-2-phenylindole, dihydrochloride). Fluorescent staining of senescence associated heterochromatin foci. To visualize senescence-associated heterochromatin foci, DAPI was used to stain for DNA after fixation and permeabilization of the cells. The cells were examined by fluorescence microscopy (Zeiss Axiophot, Jena, Germany). Fluorescence intensities from images of six randomly selected microscopic fields of cells were semi-quantitatively analyzed by densitometry (ImageJ software, NIH Image). The Corrected Total Cell Fluorescence (CTCF) was calculated by the formula: CTCF ¼ integrated density À (area of selected cell Â mean fluorescence of background readings).
Immunohistochemistry
OCT4 was analyzed by immunohistochemistry using the anti-OCT4 (Santa Cruz Biotecnology, sc-5279) in a series of mesothelioma patients subjected to surgery at the Regina Elena Cancer Institute (Rome, Italy) between 2005 and 2008. Formalin-fixed and paraffin-embedded 5 mm sections were stained with haematoxylin and eosin or stained with anti-Oct-4 antibody (SC5279, Santa Cruz, 1:50, BENCHMARK ULTRA VENTANA, Roche, Tucson, AZ, USA). Seven randomly chosen fields from each sample were scored.
Flow cytometry
Cells were detached by PBS/EDTA 2 mM, fixed/permeabilized in 80% methanol (10 min on ice), washed twice with PBS1 Â and resuspended for ab staining at 1 Â 10 6 cells/100 ml in PBS/BSA1%.The following antibodies were used: anti-OCT4 rabbit monoclonal (Invitrogen), IgG2a isotype matched negative control (Invitrogen), AlexaFluor-488 conjugated antirabbit antibody. Data were acquired using a FACS CALIBUR instrument and analysis was performed by using FlowingSoftware 2.0 (Cell Imaging Core, University of Turku, Turku, Finland).
Apoptosis detection
Dead and apoptotic cells were measured by FACS analysis after propidium iodide/Annexin-V staining (Vybrant Apoptosis Assay Kit #3, Life Technologies, Grand Island, NY, USA), according to the manufacturer's instructions.
Xenograft transplantation
Suspensions of 3 Â 10 6 MSTO-211H cells were injected subcutaneously in PBS 1x/Matrigel (BD Biosciences San Jose, CA, USA) into 5-week-old male SCID mice (Charles River, Milan). Body weight and clinical signs of the mice were determined every 3 days. Tumor volume was calculated by using the formula: V ¼ p/6 Â length Â width (by manual caliper). All tumorigenicity assays were performed according to the guidelines set by the internal ethical committee.
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